SCF-PCR BRAID™ → DRUG MAPPING MATRIX | LONG-COVID

FUNCTIONAL CURE ORIENTATION

LONG-COVID (PASC) — FDA-ALIGNED THERAPEUTIC TRANSLATION

Framework Code: SCF-LC-PCRB-DM-001

Scope: FDA-Approved + Late-Stage / Pre-Approved Agents

Objective: Map SCF mechanisms → real-world pharmacologic interventions

STRATEGIC PRINCIPLE

A functional cure in Long-COVID requires:

Simultaneous suppression of disease drivers
Removal of pathological structures
Restoration of system function

→ Achieved via multi-drug SCF-PCR braid alignment

PREVENTATIVE STRAND (P)

Mechanism → Drug Mapping

2.1 NF-κB / IL-6 / Cytokine Suppression

Target	Drug	Class	Status
IL-6 receptor	Tocilizumab	Monoclonal antibody	FDA-approved
IL-6 receptor	Sarilumab	Monoclonal antibody	FDA-approved
JAK/STAT pathway	Baricitinib	JAK inhibitor	FDA-approved
TNF-α	Adalimumab / Infliximab	TNF inhibitors	FDA-approved

2.2 Broad Anti-Inflammatory Modulation

Target	Drug	Class
NF-κB suppression	Dexamethasone	Corticosteroid
COX pathway	Aspirin	NSAID
Colchicine pathway	Colchicine	Inflammasome modulator

2.3 Endothelial Stabilization

Target	Drug	Mechanism
vWF-mediated adhesion	Caplacizumab	vWF inhibitor
NO signaling	Sildenafil	PDE5 inhibitor
RAAS modulation	Losartan	ARB

2.4 Complement Inhibition

Target	Drug
C5	Eculizumab
C5	Ravulizumab

CURATIVE STRAND (C)

Mechanism → Drug Mapping

3.1 Antiviral (Viral Persistence)

Target	Drug	Mechanism
SARS-CoV-2 protease	Nirmatrelvir (Paxlovid)	Protease inhibitor
RNA polymerase	Remdesivir	RdRp inhibitor
Broad antiviral	Molnupiravir	Nucleoside analog

3.2 Fibrinolytic Activation (Microclots)

Target	Drug	Class
Plasminogen activation	Alteplase (tPA)	Thrombolytic
Plasminogen activation	Tenecteplase	Thrombolytic
Direct fibrinolysis	Urokinase	Enzyme

3.3 Anticoagulation (Clot Prevention)

Target	Drug	Class
Factor Xa	Apixaban / Rivaroxaban	DOAC
Thrombin	Dabigatran	Direct inhibitor
Broad coagulation	Heparin / LMWH	Anticoagulant

3.4 Antifibrinolytic Inhibition (Key Bottleneck)

Target	Drug	Status
PAI-1	Tiplaxtinin (investigational)	Preclinical/Phase
α2-antiplasmin	Experimental inhibitors	Emerging

3.5 Anti-Amyloid / Clot Structure Disruption

Target	Drug	Status
Amyloid fibrin	Doxycycline (anti-amyloid effects)	FDA-approved
Protein misfolding	TUDCA	Investigational/clinical use

RESTORATIVE STRAND (R)

Mechanism → Drug Mapping

4.1 Mitochondrial Restoration

Target	Drug	Mechanism
AMPK activation	Metformin	Energy regulation
NAD⁺ metabolism	Nicotinamide (Niacin)	NAD⁺ precursor
Mitochondrial ROS	CoQ10	ETC support

4.2 Neuroimmune Modulation

Target	Drug	Mechanism
Microglial activation	Minocycline	Anti-inflammatory
CNS inflammation	Fluvoxamine	Sigma-1 receptor
Vagus nerve tone	Ivabradine (indirect HR control)	Autonomic modulation

4.3 Endothelial & ECM Repair

Target	Drug	Mechanism
Endothelial function	Statins (Atorvastatin)	Anti-inflammatory + vascular
Fibrosis modulation	Pirfenidone	Anti-fibrotic
Fibrosis modulation	Nintedanib	Tyrosine kinase inhibitor

4.4 Microbiome Restoration

Target	Drug/Agent
Dysbiosis	Rifaximin
Microbiome	Probiotics (clinical adjuncts)

INTEGRATED SCF FUNCTIONAL CURE STACK

5.1 Core Multi-Drug Architecture

SCF Role	Drug Class	Example
Target Modulator	Antiviral	Paxlovid
Structural Disruptor	Fibrinolytic	Alteplase
Resistance Blocker	Anti-inflammatory	Baricitinib
Endothelial Stabilizer	Statin / ARB	Atorvastatin
Metabolic Restorer	Mitochondrial	Metformin

5.2 Example SCF-PCR Combination

Curative Core:

Paxlovid + Alteplase

Preventative Shield:

Baricitinib + Aspirin

Restorative Layer:

Metformin + Statin + NAD⁺ precursor

SYNERGY & RESISTANCE PREVENTION

6.1 Why Combination is Required

Monotherapy	Limitation
Antiviral	Does not remove microclots
Fibrinolytic	Clots reform due to inflammation
Anti-inflammatory	Does not remove existing pathology

6.2 SCF Multi-Target Advantage

Blocks all major feedback loops simultaneously
Prevents pathological re-stabilization
Enables system-wide reset

SAFETY & REGULATORY STRATEGY

7.1 Regulatory Pathway

505(b)(2) for combination repositioning
IND for novel combinations
Biomarker-driven adaptive trials

7.2 Safety Considerations

Risk	Mitigation
Bleeding (fibrinolytics)	Controlled dosing + monitoring
Immunosuppression	Targeted cytokine inhibition
Drug interactions	PK/PD modeling

FINAL SYNTHESIS

Functional Cure Definition (SCF Context):

Sustained elimination of pathological drivers + restoration of system coherence + absence of relapse

SCF-PCR DRUG LOGIC

Preventative: Stops re-lock-in
Curative: Removes root pathology
Restorative: Rebuilds system

Together → Collapse of disease state

FINAL STATEMENT

A functional cure for Long-COVID is achievable only through a coordinated, multi-drug SCF-PCR braid that simultaneously targets viral persistence, microclot pathology, immune dysregulation, and mitochondrial dysfunction using FDA-aligned therapeutics.